


Pressure Enabled Drug Delivery™ — Clinical Evidence

Resonance of multiple clinical studies with different therapeutics



**Multiple studies agree:
PEDD improves drug delivery and tumor response.**

EH catheter = endhole catheter

References:

1. Titano JJ, Fischman AM, Cherian A, et al. End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis. *Cardiovasc Intervent Radiol.* 2019;42(4):560-568. doi:10.1007/s00270-018-2150-6.
2. Katz SC, Moody AE, Guha P, et al. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. *J Immunother Cancer.* 2020;8(2):e001097
3. Kapoor, B. et al. 3:18 PM Abstract No. 133 Surefire Infusion System (SIS) hepatocellular carcinoma registry study interim results: a multicenter study of the safety, feasibility, and outcomes of the SIS expandable-tip microcatheter in DEB-TACE. *J. Vasc. Interv. Radiol.* 29, S60 (2018).
4. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol.* 2010;33(1):41-52. doi:10.1007/s00270-009-9711-7
5. d'Abadie P, et al. Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres. *Diagn Interv Radiol* 2021; 27:768-773.
6. Katz, et al. "HITM-SURE: Phase Ib CAR-T hepatic artery infusion trial for stage IV adenocarcinoma using Pressure-Enabled Drug Delivery technology." SITC (2018) Poster Presentation.
7. Pasciak AS, McElmurray JH, Bourgeois AC, Heidel RE, Bradley YC. The impact of an antireflux catheter on target volume particulate distribution in liver-directed embolotherapy: a pilot study. *J Vasc Interv Radiol.* 2015;26(5):660-669. doi:10.1016/j.jvir.2015.01.029

This summary is sponsored by TriSalus Life Sciences[®]. Results are not predictive of outcomes in other cases.

INTENDED USE: The TriNav Infusion System is intended for use in angiographic procedures. It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.

CONTRAINDICATIONS: TriNav is not intended for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).

Rx ONLY. For the safe and proper use of the TriNav device, refer to the Instructions for Use.